Two-Component Capsule for Rapid ASA Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ASA formulations for myocardial infarction treatment require water for dissolution and adequate saliva production, leading to delayed administration in emergency situations, as they have poor solubility and are unstable in aqueous solutions.
Innovation Solution
A two-component composition comprising ASA in one compartment and an aqueous solution of a pharmaceutically acceptable salt of an organic acid in another, which quickly mixes to form a ready-to-use ASA solution, independent of water or saliva availability, using a capsule design with separate chambers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If effervescent tablets containing ASA are used for immediate treatment, then ASA can be administered quickly, but the tablets require water for dissolution and adequate saliva production, causing delays in emergency situations
Solution Approach 1:
The capsule is divided into two separate compartments: the first compartment contains ASA in dry powder or granule form, while the second compartment contains an aqueous solution of a salt of an organic acid. This segmentation allows each component to be optimized independently - the dry ASA avoids premature hydrolysis while the pre-prepared aqueous solution eliminates the need for additional water during administration.
Solution Approach 2:
The aqueous solution of the organic acid salt is prepared in advance in the second compartment, ready to immediately dissolve the ASA when the compartments are mixed. This preliminary preparation of the dissolution medium eliminates the delay associated with requiring the patient to have water available or produce sufficient saliva during an emergency.
2Reliability
If ASA is dissolved in water for quick administration, then bioavailability is improved, but ASA hydrolyses rapidly in water making storage of dissolved ASA difficult
Solution Approach 1:
By separating ASA into a distinct dry compartment from the aqueous environment, the invention prevents contact between water and ASA during storage. The ASA remains in a stable dry state until the moment of administration, when the compartments are mixed and ASA rapidly dissolves in the pre-prepared aqueous solution of organic acid salt.
Solution Approach 2:
The organic acid salt serves as an intermediary substance that facilitates rapid dissolution of ASA while providing a chemically stable environment. The salt creates a buffered aqueous solution that allows ASA to dissolve quickly for high bioavailability while the specific chemical composition prevents rapid hydrolysis during the brief period before administration.
3Device complexity
If conventional ASA formulations are used, then they are simple in design, but they require water and saliva for dissolution leading to delayed treatment
Solution Approach 1:
The invention merges two previously separate requirements into a single self-contained unit: the dry ASA powder and the aqueous dissolution medium are combined in a single capsule with two compartments. This eliminates the need for external water sources or adequate saliva production, as all necessary components are integrated within the capsule itself.
Solution Approach 2:
The aqueous solution of organic acid salt is prepared in advance within the capsule, ready to immediately dissolve ASA upon mixing. This preliminary preparation of the dissolution medium within the capsule structure eliminates treatment delays caused by needing to locate water or wait for saliva production during cardiac emergencies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid dissolution and administration of ASA within 10-20 seconds, ensuring quick treatment of myocardial infarction without the need for water or saliva, providing a stable and effective emergency medication.
Implementation Method 1
the second component comprises an aqueous solution comprising a salt of an organic acid... enables an immediate dissolution of ASA upon mixing of the first and second components
Data Source
AI summary
Described herein is a novel two-component composition including acetylsalicylic acid (ASA) and which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration such as to treat imminent myocardial infarction in a person in need thereof.